Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with LenvatinibHaruki Uojima, Wasaburo Koizumi, Makoto Kako et al.|Liver Cancer|2019Cited by 91
<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>Katsuaki Ogushi, Shin Maeda, Makoto Ueno et al.|Clinical and Experimental Gastroenterology|2020Cited by 55
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Cancers|2020Cited by 54
Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosisHaruki Uojima, Shuzo Kobayashi, Seiko Sakurai et al.|European Journal of Gastroenterology & Hepatology|2017Cited by 43
Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascitesHaruki Uojima, Makoto Kako, Takeshi Kinbara et al.|Hepatology Research|2016Cited by 27